Stoke Therapeutics Collaborates on GeneDx's New Pediatric Epilepsy Genetic Testing Access Program

GeneDx Launches Patient Access Program to Enhance Genetic Testing for Pediatric Epilepsy

In a significant development within the biopharmaceutical industry, GeneDx, a leader in genomic insights, launches a Patient Access Program aimed at addressing the challenges faced by pediatric patients suffering from epilepsy. The initiative, developed in collaboration with Biogen, Praxis Precision Medicines, and Stoke Therapeutics, seeks to alleviate the prolonged 5–8-year diagnostic journey that many children endure before receiving a definitive diagnosis. With epilepsy affecting nearly half a million children in the United States, the need for improved access to genetic testing has never been more critical.

The current landscape of genetic testing for epilepsy highlights a substantial gap in diagnostic capabilities. While numerous genes are associated with seizures—over 700 in total—most commercial gene panels fail to cover more than 50% of these genes. Traditional gene panels yield a diagnostic rate of only 19%, whereas whole exome sequencing (WES) has demonstrated the potential to provide genetic diagnoses for nearly 25% of seizure patients. These statistics underscore the recommendation from both the National Society of Genetic Counselors and the American Epilepsy Society advocating for the use of exome testing as a first-line approach for unexplained epilepsy. GeneDx’s initiative to enhance access to this advanced testing method aims to bridge these gaps and promote equitable care for pediatric patients across diverse backgrounds.

Furthermore, the insights gained from the Patient Access Program will significantly contribute to GeneDx's already extensive database of over 700,000 exome and genome results. This wealth of data will not only assist in ongoing research into gene-disease relationships but also pave the way for future personalized treatments and therapies. Melanie Duquette, Chief Growth Officer of GeneDx, emphasizes the importance of understanding the genetic origins of epilepsy, which is pivotal in developing effective interventions. By improving access to genetic testing, this program does not merely seek to provide answers for patients but also plays a crucial role in the biopharma sector's ongoing research and development efforts.

In addition to bolstering genetic testing capabilities, the initiative addresses the disparities in access that have long hindered effective treatment for many families. By making whole exome sequencing more widely available, GeneDx aims to democratize access to crucial diagnostic tools, ultimately improving the outcomes for children with epilepsy. The collaboration with industry partners like Stoke Therapeutics reinforces the collective commitment to advancing healthcare solutions tailored to the unique needs of pediatric patients.

As the initiative gains momentum, it highlights a pivotal shift in how the biopharmaceutical industry approaches genetic diagnostics for complex conditions like epilepsy. The ongoing collaboration between leading companies not only enhances the potential for breakthroughs in understanding and treating seizure-related disorders but also illustrates a broader trend towards more personalized and equitable healthcare solutions in the genomic landscape.